Hedge funds cut NFLX, keep big bets on MSFT, AMZN, add NVDA
Investing.com - Chemomab Therapeutics DRC reported on Friday third quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
Chemomab Therapeutics DRC announced earnings per share of $-0.04 on revenue of $0.00. Analysts polled by Investing.com EPS of $-0.19 on revenue of $0.00.
Chemomab Therapeutics DRC 's are down 90% and is trading at $2.15 , still down 79.91% from its 52 week high of $10.70 set on Monday, November 15, 2021.
Chemomab Therapeutics DRC shares gained 3.37% to trade at $2.15 in intra-day trade the report.
Chemomab Therapeutics DRC follows other major Healthcare sector earnings this month
Chemomab Therapeutics DRC's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar